Affinage

CCL1

C-C motif chemokine 1 · UniProt P22362

Length
96 aa
Mass
11.0 kDa
Annotated
2026-04-28
100 papers in source corpus 38 papers cited in narrative 38 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CCL1 (I-309) is a CC chemokine that functions as a monocyte/macrophage chemoattractant, anti-apoptotic survival factor, angiogenic mediator, and key regulator of regulatory T cell recruitment and immune homeostasis. CCL1 signals primarily through the Gi-coupled receptor CCR8 (Kd ~1–2 nM), activating calcium mobilization, the RAS/ERK MAPK pathway for anti-apoptotic signaling, and JAK/STAT pathways in context-dependent settings, while also engaging a second receptor, AMFR, to drive fibroblast activation via Spry1 ubiquitination/ERK disinhibition and macrophage M2 polarization via CREB/C/EBPβ signaling (PMID:1557400, PMID:9207005, PMID:12645948, PMID:34407391, PMID:37220693). CCL1 is an obligate monomer enforced by a unique third disulfide bond (C26–C68) required for secretion, and its bioactivity is modulated by C-terminal processing by carboxypeptidase M, N-glycosylation state, and post-transcriptional regulation including miR-20a-5p targeting and ALKBH5-mediated m6A-dependent mRNA destabilization (PMID:8077676, PMID:22479563, PMID:24644239, PMID:40254698). Transcription of CCL1 is controlled by AhR, NF-κB, c-Myc, and c-Jun/c-Fos downstream of ERK, and its expression defines specific immune activation states including M2b macrophage polarization and ILC2 autocrine proliferation (PMID:16679317, PMID:18981157, PMID:16735693, PMID:31537642, PMID:38652401).

Mechanistic history

Synthesis pass · year-by-year structured walk · 22 steps
  1. 1992 High

    Establishing CCL1's fundamental identity as a monocyte-selective chemoattractant resolved which leukocyte populations respond to this chemokine and demonstrated its capacity to mobilize intracellular calcium specifically in monocytes.

    Evidence Purified recombinant I-309 tested in chemotaxis and calcium flux assays across monocytes, lymphocytes, and neutrophils

    PMID:1557400

    Open questions at the time
    • Receptor identity unknown
    • In vivo relevance of monocyte chemotaxis not tested
    • Signaling pathway downstream of calcium flux uncharacterized
  2. 1994 High

    Demonstrating that CCL1 is an obligate monomer due to a unique third disulfide bond (C26–C68) distinguished it structurally from all other chemokines and showed this bond is required for protein secretion.

    Evidence Size exclusion HPLC, ultracentrifugation, cross-linking, and C26/C68 site-directed mutagenesis

    PMID:8077676

    Open questions at the time
    • Atomic-resolution structure not yet determined
    • Whether monomeric state affects receptor binding unknown
  3. 1996 High

    Discovery of CCL1's anti-apoptotic activity through a pertussis toxin-sensitive (Gi-coupled) receptor established a non-chemotactic survival function unique among chemokines.

    Evidence Dexamethasone-induced apoptosis assay in BW5147 lymphoma cells with pertussis toxin inhibition

    PMID:8805659

    Open questions at the time
    • Identity of the Gi-coupled receptor mediating this effect not yet known
    • Downstream signaling pathway from Gi to anti-apoptosis uncharacterized
  4. 1997 High

    Identification of CCR8 as the specific, high-affinity receptor for CCL1 resolved the receptor identity question, showing exclusive ligand–receptor pairing with Gi coupling, calcium flux, and chemotaxis at nanomolar concentrations.

    Evidence CCR8 transfection into pre-B cells with calcium flux, chemotaxis, radioligand binding (Kd ~1.2 nM), and pertussis toxin sensitivity; independently replicated

    PMID:9207005 PMID:9211859

    Open questions at the time
    • Structural basis of CCL1–CCR8 interaction unknown
    • Whether additional receptors exist unaddressed
  5. 1998 High

    Showing that CCL1 blocks CCR8-dependent HIV-1 entry revealed a viral coreceptor function for CCR8 and positioned CCL1 as a natural inhibitor of HIV infection.

    Evidence HIV-1 infection and cell–cell fusion assays with I-309 inhibition of CCR8-mediated viral entry

    PMID:9417093

    Open questions at the time
    • Therapeutic potential of CCL1 as HIV entry inhibitor not tested in vivo
    • Mechanism of CCR8-mediated viral entry not structurally defined
  6. 2000 High

    Multiple studies established CCL1 as an angiogenic factor acting through CCR8 on endothelial cells, and as a downstream mediator of apolipoprotein(a)-induced monocyte recruitment, broadening CCL1's roles beyond leukocyte chemotaxis to vascular biology. Concurrently, the NMR solution structure revealed the monomeric fold with a truncated C-terminal helix imposed by the third disulfide bond.

    Evidence Endothelial chemotaxis/invasion/Matrigel/in vivo angiogenesis assays; apo(a)-induced CCL1 ELISA with antibody/antisense inhibition; 1H NMR structure determination

    PMID:10821677 PMID:10942748 PMID:11110671 PMID:11133740

    Open questions at the time
    • Structural basis of CCR8 activation by CCL1 at atomic resolution not resolved
    • Relative contributions of angiogenesis vs. chemotaxis in vivo not dissected
  7. 2001 High

    Identification of an autocrine CCL1–CCR8 anti-apoptotic loop in adult T-cell leukemia cells established a cancer-relevant survival mechanism exploiting this chemokine axis.

    Evidence Gene expression profiling, anti-I-309 antibody neutralization of supernatant activity, pertussis toxin sensitization to apoptosis in ATL cultures

    PMID:11493464

    Open questions at the time
    • Whether this autocrine loop is a general feature of CCR8+ malignancies unknown
    • Downstream signaling mediating anti-apoptosis in ATL not mapped
  8. 2003 High

    Dissection of the RAS/ERK MAPK pathway as the downstream effector of CCL1–CCR8 anti-apoptotic signaling answered how Gi-coupled receptor engagement translates into survival, with MEK inhibitor and dominant-negative M-RAS blocking the effect.

    Evidence ERK1/2 phosphorylation, PD98059 MEK inhibition, dominant-negative M-RAS in CCR8-transfected CHO and BW5147 cells

    PMID:12645948

    Open questions at the time
    • Downstream targets of ERK mediating survival not identified
    • Whether PI3K/AKT contributes was not tested
  9. 2006 High

    Three studies collectively established the transcriptional regulation of CCL1: AhR directly binds the CCL1 promoter in macrophages exposed to polycyclic aromatic hydrocarbons; CCL1 production requires co-engagement of FcγRII and MyD88 signals (defining M2b macrophage state); and the CCL1 N-terminus is critical for CCR8 binding as shown by ligand/receptor mutagenesis.

    Evidence ChIP/EMSA for AhR at CCL1 promoter with siRNA knockdown; systematic cytokine/FcγR co-stimulation; site-directed mutagenesis of CCL1 N-terminus and CCR8 with calcium/chemotaxis readouts

    PMID:16679317 PMID:16735693 PMID:17023422

    Open questions at the time
    • Full promoter regulatory map not assembled
    • AhR and FcγRII signals not integrated in a unified regulatory model
  10. 2007 High

    Genetic and antibody evidence in peritoneal adhesion models showed CCL1–CCR8 mediates macrophage aggregation and tissue remodeling, extending CCL1's role to wound healing and fibrotic pathology.

    Evidence CCR8-knockout mice and anti-CCL1 neutralizing antibody in peritoneal adhesion model with cell aggregation assays

    PMID:17404314

    Open questions at the time
    • Molecular mechanism linking CCR8 signaling to macrophage aggregation not defined
    • Contribution of other CCR8 ligands not excluded
  11. 2008 High

    Two studies mapped additional transcriptional control: ERK-dependent c-Jun/c-Fos and p38-mediated mRNA stabilization govern OSM-induced CCL1 expression, while CCL1-deficient mice demonstrated that statin-mediated Treg recruitment and anti-inflammatory effects require CCL1 in vivo.

    Evidence siRNA knockdown of ERK/c-Jun/c-Fos, mRNA half-life measurements, CCL1-deficient mice in delayed-type hypersensitivity model

    PMID:18714025 PMID:18981157

    Open questions at the time
    • Whether c-Jun/c-Fos directly bind CCL1 promoter (ChIP) not shown in this study
    • Statin–CCL1 mechanism at the molecular level not detailed
  12. 2009 High

    NF-κB was established as a direct transcriptional activator of CCL1 downstream of TNFα, with EMSA confirming NF-κB binding to the CCL1 promoter in lipoprotein(a)-stimulated macrophages.

    Evidence NF-κB inhibitor Bay 11-7082, anti-TNFα neutralization, EMSA

    PMID:19302817

    Open questions at the time
    • Specific NF-κB binding site in CCL1 promoter not mapped at nucleotide resolution
    • Interplay between NF-κB and AhR at the promoter not addressed
  13. 2010 Medium

    Demonstrating that CCL1 neutralization prevents de novo Treg conversion and suppressive function, and that combined anti-CCL1 plus CpG treatment achieves complete tumor rejection, established CCL1 as a therapeutic target for tumor immune evasion.

    Evidence Anti-CCL1 neutralizing antibody in BALB-neuT tumor model with Treg flow cytometry

    PMID:20483762

    Open questions at the time
    • Single mouse tumor model; generalizability to other tumor types not tested
    • Direct mechanism of CCL1 in Treg conversion (signaling pathway) not elucidated
  14. 2012 High

    Two discoveries refined CCL1 biology: carboxypeptidase M was identified as a C-terminal processing enzyme that enhances CCR8-mediated calcium signaling and anti-apoptotic potency of CCL1, and CCL1 was identified as the secreted mediator linking RhoA activation to JAK-STAT3 signaling.

    Evidence Mass spectrometry identification of CPM cleavage products, calcium flux/apoptosis assays; bacterial CNF toxin/RhoA activation with siRNA pathway dissection

    PMID:22311973 PMID:22479563

    Open questions at the time
    • In vivo relevance of CPM processing not demonstrated
    • Whether JAK-STAT3 is a general CCL1–CCR8 downstream pathway or context-specific unclear
  15. 2013 High

    CCL1 expressed by lymph node lymphatic sinuses was shown to control tumor cell entry into lymph nodes via CCR8, while spinal CCL1–CCR8 signaling was found to modulate excitatory synaptic transmission via NMDA receptor phosphorylation, revealing roles in metastasis and neuropathic pain.

    Evidence CCR8 shRNA/antagonist in mouse metastasis model with intravital imaging; patch-clamp electrophysiology, intrathecal CCL1, NMDA receptor phosphorylation assay, behavioral pain testing

    PMID:23788036 PMID:23878309

    Open questions at the time
    • Mechanism by which CCR8 drives NMDA receptor phosphorylation not fully mapped
    • Whether lymphatic CCL1 drives metastasis in human cancers not established
  16. 2014 High

    Crystal structures of Ser-CCL1 (glycosylated and non-glycosylated) at 2.1–2.7 Å resolution, combined with chemotaxis assays on chemically synthesized glycoforms, demonstrated that N-glycosylation modulates CCL1 chemotactic potency without altering the protein fold.

    Evidence Total chemical synthesis by native chemical ligation, quasi-racemic X-ray crystallography, chemotaxis assays comparing defined glycoforms

    PMID:24644239 PMID:24692304

    Open questions at the time
    • Structure of the CCL1–CCR8 complex not determined
    • Physiological glycoform heterogeneity and its functional impact in vivo unknown
  17. 2017 Medium

    CCL1 transcription was linked to epigenetic regulation: Sox2 reduces H3K27Me3 on the CCL1 promoter to activate NF-κB–CCL1 signaling for Treg recruitment in breast cancer, while miR-20a-5p directly targets the CCL1 3'UTR to suppress expression, with its loss by promoter methylation elevating CCL1.

    Evidence ChIP for H3K27Me3, NF-κB reporter, Treg recruitment assay; luciferase reporter for miR-20a-5p targeting of CCL1 3'UTR, bisulfite sequencing

    PMID:28972028 PMID:29044882

    Open questions at the time
    • Each finding from a single lab; independent replication pending
    • Whether Sox2-mediated epigenetic changes directly alter CCL1 promoter accessibility not shown by ATAC-seq or equivalent
  18. 2019 High

    Genetic studies expanded CCL1's physiological roles: CCL1/ApoE double-knockout mice showed enhanced atherosclerosis with reduced Treg content, while activated ILC2s were identified as a major CCL1 source operating an autocrine CCR8 feed-forward loop to support ILC2 proliferation during helminth infection.

    Evidence CCL1/ApoE double-KO and LDLR-null mice with CCR8 blockade, intravital microscopy; CCR8-deficient mice in helminth infection model with ILC2 proliferation assays

    PMID:31121182 PMID:31537642

    Open questions at the time
    • Whether CCL1 deficiency alone (without ApoE deletion) alters atherosclerosis not tested
    • Signaling downstream of CCR8 in ILC2 proliferation not dissected
  19. 2021 High

    AMFR was identified as a second functional CCL1 receptor that drives fibroblast activation through Spry1 ubiquitination and ERK disinhibition, establishing a dual-receptor model (CCR8 for migration, AMFR for activation) in pulmonary fibrosis; spinal CCL1 was also shown to produce analgesia via microglial CCR8 and kappa-opioid receptor/dynorphin release.

    Evidence Mass spectrometry of CCL1 protein complexes (AMFR identification), conditional Ccl1/Ccr8/Amfr deletions in fibroblasts and macrophages, ubiquitination assays; intrathecal CCL1 with opioid receptor antagonists and microglial inhibitor

    PMID:33905573 PMID:34407391

    Open questions at the time
    • AMFR–CCL1 binding interface not structurally characterized
    • Whether AMFR mediates CCL1 signaling in non-fibrotic contexts unknown
    • Dynorphin release mechanism downstream of CCR8 on microglia not detailed
  20. 2023 High

    The AMFR-dependent M2 macrophage polarization pathway was mechanistically defined: CCL1 signals through AMFR to activate CREB/C/EBPβ, driving M2 polarization that contributes to pulmonary fibrosis; macrophage-specific AMFR or CCR8 deletion each protected against bleomycin-induced fibrosis.

    Evidence Macrophage-specific AMFR and CCR8 knockout mice, CREB/C/EBPβ signaling assays, bleomycin model, M2 marker flow cytometry

    PMID:37220693

    Open questions at the time
    • Whether CREB/C/EBPβ is the sole AMFR downstream pathway or one of several not determined
    • Relative contributions of fibroblast vs. macrophage AMFR signaling not quantified
  21. 2024 Medium

    c-Myc was established as a direct transcriptional activator of CCL1 by ChIP, adding to the set of known transcription factors; HDAC2 inhibition (SAHA) suppresses c-Myc occupancy at the CCL1 promoter and reduces Treg recruitment in glioma.

    Evidence ChIP for c-Myc at CCL1 promoter, dual-luciferase reporter, HDAC2 inhibition, intracranial xenograft model

    PMID:38652401

    Open questions at the time
    • Single lab; independent replication pending
    • Whether c-Myc cooperates with NF-κB or AhR at the CCL1 promoter not tested
  22. 2025 Medium

    Post-transcriptional regulation of CCL1 was expanded: ALKBH5-mediated m6A erasure destabilizes Ccl1 mRNA, and ALKBH5 deletion or inhibition increases CCL1 expression and Treg recruitment, protecting against acute lung injury; separately, CCL1–CCR8 signaling through JAK/STAT was confirmed to activate hepatic stellate cells in liver fibrosis.

    Evidence Alkbh5-KO/KI mice, m6A dot assay, RIP for ALKBH5–Ccl1 mRNA binding, LPS ALI model; co-culture with JAK/STAT inhibitors in liver fibrosis model

    PMID:40122149 PMID:40254698

    Open questions at the time
    • Specific m6A sites on CCL1 mRNA not mapped
    • Whether ALKBH5 regulation is tissue-specific not addressed
    • JAK/STAT activation in HSCs studied in single lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the atomic-resolution structure of the CCL1–CCR8 and CCL1–AMFR complexes, the full integration of transcriptional and post-transcriptional regulatory inputs (AhR, NF-κB, c-Myc, c-Jun/c-Fos, miR-20a-5p, ALKBH5/m6A) into a unified promoter/mRNA regulatory model, and whether AMFR functions as a CCL1 receptor beyond fibrotic contexts.
  • No CCL1–CCR8 or CCL1–AMFR co-crystal structure
  • Integrated promoter regulatory model not constructed
  • AMFR receptor function in non-fibrotic tissues unexplored
  • Physiological glycoform heterogeneity of CCL1 and its functional impact in vivo undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0048018 receptor ligand activity 5 GO:0098772 molecular function regulator activity 3
Localization
GO:0005576 extracellular region 5
Pathway
R-HSA-162582 Signal Transduction 6 R-HSA-168256 Immune System 5 R-HSA-1643685 Disease 3 R-HSA-5357801 Programmed Cell Death 3
Partners
ALKBH5AMFRCCR8CPM

Evidence

Reading pass · 38 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1992 CCL1 (I-309) is a monocyte-specific chemoattractant: purified recombinant I-309 stimulated migration of human monocytes but not neutrophils in vitro, and transiently increased cytoplasmic free calcium in monocytes but not lymphocytes or neutrophils. In vitro chemotaxis assay and intracellular calcium measurement with purified recombinant protein Proceedings of the National Academy of Sciences of the United States of America High 1557400
1994 I-309 (CCL1) remains a strict monomer at all concentrations tested, unlike other chemokines (IL-8, MCP-1) that dimerize at high concentrations; this is due to a unique intramolecular disulfide bond between C26 and C68, whose integrity is required for protein secretion as shown by site-directed mutagenesis. Size exclusion HPLC, sedimentation equilibrium ultracentrifugation, chemical cross-linking, cyanogen bromide/trypsin digestion, site-directed mutagenesis Journal of immunology (Baltimore, Md. : 1950) High 8077676
1996 CCL1 (I-309) protects murine T-cell lymphoma lines (BW5147) against dexamethasone-induced apoptosis; this anti-apoptotic activity is blocked by pertussis toxin, indicating it is mediated through a Gi-coupled receptor, and is specific to CCL1/TCA-3 among chemokines tested. Cell viability/apoptosis assay with pertussis toxin inhibition; cross-comparison with multiple chemokines Journal of immunology (Baltimore, Md. : 1950) High 8805659
1997 CCR8 is the specific receptor for CCL1 (I-309): transfection of CCR8 (CY6/TER1/CKR-L1) into mouse pre-B cells conferred calcium flux and chemotaxis in response to I-309 (EC50 ~2 nM), while 20 other chemokines were inactive; signaling was pertussis toxin-sensitive, indicating Gi coupling. Receptor transfection into pre-B cell line, calcium flux assay, chemotaxis assay, pertussis toxin inhibition The Journal of experimental medicine High 9207005 9211859
1997 CCR8 (then called CKR-L1/TER1) binds I-309 with high affinity (Kd ~1.2 nM), induces intracellular Ca2+ mobilization and chemotaxis in transfected cells in a pertussis toxin-sensitive manner, confirming Gi-protein coupling; signaling was blocked by cholera toxin-insensitive pathways. 125I-I-309 radioligand binding (Scatchard), calcium mobilization, chemotaxis in transfected 300-19 pre-B cells, pertussis/cholera toxin inhibition The Journal of biological chemistry High 9211859
1998 CCL1 (I-309) inhibits CCR8-dependent HIV-1 infection: CCR8 serves as a coreceptor for diverse T-cell tropic, dual-tropic, and macrophage-tropic HIV-1 strains, and I-309 potently inhibits HIV-1 envelope-mediated cell-cell fusion and virus infection through CCR8. HIV infection assay, cell-cell fusion assay, flow cytometry, immunohistochemistry with anti-CCR8 antibodies The Journal of biological chemistry High 9417093
1998 Murine CCR8 is the receptor for both I-309 (human CCL1) and TCA-3 (murine CCL1 ortholog): both ligands induced calcium mobilization in mCCR8-transfected 293-EBNA cells; TCA-3 binds mCCR8 with high affinity (Kd ~2 nM) and is only partially competed by I-309, suggesting partial cross-reactivity. Receptor cloning, transfection into 293-EBNA cells, calcium mobilization assay, 125I-TCA-3 radioligand binding Journal of immunology (Baltimore, Md. : 1950) High 9469461
2000 I-309 (CCL1) acts as an angiogenic molecule: it binds to human umbilical vein endothelial cells (HUVECs) via CCR8, stimulates endothelial chemotaxis and invasion, promotes capillary-like structure formation in Matrigel in vitro, and induces angiogenesis in vivo in rabbit cornea and chick chorioallantoic membrane assays. RT-PCR and RNase protection assay for CCR8 expression; in vitro chemotaxis, invasion, and Matrigel assays; in vivo cornea and CAM angiogenesis assays Blood High 11110671
2000 CCR8 mediates endothelial cell chemotaxis induced by I-309, vMIP-I, and apolipoprotein(a)-stimulated conditioned medium; inhibition by anti-CCR8 antibody and pertussis toxin confirmed receptor-mediated, Gi-coupled signaling in endothelial cells expressing CCR8. Endothelial cell chemotaxis assay, antibody neutralization, pertussis toxin inhibition, RNA blot analysis, immunohistochemistry Blood High 11133740
2000 Apolipoprotein(a) [apo(a)] induces CCL1 (I-309) production by human vascular endothelial cells, which is responsible for monocyte chemotactic activity; the carboxy-terminal domain of apo(a) is the active moiety; anti-I-309 antibodies, anti-CCR8 antibody, and I-309 antisense oligonucleotides blocked the effect. ELISA, antibody neutralization, antisense oligonucleotides, immunohistochemistry, monocyte chemotaxis assay Circulation High 10942748
2001 CCL1 (I-309) is overexpressed in adult T-cell leukemia (ATL) cells and creates an antiapoptotic autocrine loop: ATL cell supernatants contain anti-apoptotic activity blocked by anti-I-309 antibodies; inhibition of CCR8 signaling by pertussis toxin increased apoptosis rate of ATL cell cultures. Gene expression comparison (array), antibody neutralization of supernatant activity, pertussis toxin inhibition of CCR8 signaling, apoptosis assay Blood High 11493464
2003 CCR8-dependent activation of the RAS/MAPK pathway mediates CCL1 anti-apoptotic activity: CCL1 up-regulates ERK1/2 phosphorylation via CCR8 in BW5147 lymphoma cells; MEK inhibitor PD98059 and dominant-negative M-RAS blocked CCL1 anti-apoptotic activity; vMIP-I (another CCR8 ligand) shares this activity. ERK1/2 phosphorylation assay, MEK inhibitor (PD98059), dominant-negative RAS expression, CCR8-transfected CHO cells, apoptosis assay European journal of immunology High 12645948
2000 The 3D solution structure of I-309 (CCL1) was determined by 1H NMR: the protein is monomeric, has a disordered N-terminal region, followed by a 3(10)-helix, triple-stranded antiparallel beta-sheet, and a C-terminal alpha-helix (truncated compared to other chemokines due to the additional disulfide bond between C26 and C68). 1H NMR spectroscopy with dynamic simulated annealing (978 experimental restraints) Biochemistry High 10821677
2006 CCL1 production in human monocytes requires obligate co-engagement of FcgammaRII and MyD88-dependent signals (IL-1beta or LPS); this combination defines an M2b (Type 2) macrophage activation state; IL-10, IL-4, and IFN-gamma inhibit CCL1 induction. ELISA for CCL1 production, cytokine treatments, FcgammaR engagement assays, transcriptional profiling Journal of leukocyte biology High 16735693
2006 CCL1 induction in human macrophages by benzo[a]pyrene (a polycyclic aromatic hydrocarbon) requires aryl hydrocarbon receptor (AhR) signaling and calcium influx: AhR inhibition or siRNA knockdown blocked CCL1 induction; TCDD activated AhR binding to a xenobiotic-responsive element in the CCL1 promoter; calcium chelation blocked CCL1 upregulation. qPCR, ELISA, siRNA knockdown, promoter reporter assay, chromatin immunoprecipitation (ChIP), EMSA, intracellular calcium measurement The Journal of biological chemistry High 16679317
2006 Structure-function analysis of CCR8 ligand interactions: CCL1 and vMIP-I are full agonists for calcium flux, chemotaxis, and receptor internalization; Ser-CCL1 (N-terminal serine extension) acts as partial agonist with reduced CCR8 affinity, indicating the CCL1 N-terminus is critical for binding to an intrahelical receptor site; Glu-286 in TM7 is required for receptor surface trafficking; CCL7 acts as a selective antagonist for viral but not host CCL1 responses at CCR8. Site-directed mutagenesis of CCR8, calcium flux assay, chemotaxis assay, receptor internalization assay, beta-arrestin dependence assay The Journal of biological chemistry High 17023422
2008 Statins (lovastatin) reduce acute inflammation and recruit regulatory T cells via CCL1: lovastatin locally upregulates CCL1 expression at inflammation sites; the anti-inflammatory effect of lovastatin was abrogated in CCL1-deficient mice, establishing a CCL1-dependent mechanism of statin-mediated immunomodulation. Mouse delayed-type hypersensitivity model, CCL1-deficient mice, flow cytometry for Treg quantification Journal of immunology (Baltimore, Md. : 1950) High 18714025
2008 Oncostatin M (OSM) induces CCL1 and CCL8 expression in primary human dermal fibroblasts via ERK1/2 and p38 MAPK pathways; c-Jun and c-Fos (ERK1/2 targets) are required for CCL1 expression; p38 stabilizes CCL1 mRNA by inhibiting tristetraprolin; constitutively active JAK2 V617F-driven STAT5 and its target CIS suppress CCL1 expression. Quantitative PCR, ELISA, siRNA knockdown of ERK1/2, c-Jun, c-Fos, STAT1/3/5; kinase inhibitors; JAK2 V617F overexpression; mRNA half-life measurement Journal of immunology (Baltimore, Md. : 1950) High 18981157
2009 Lipoprotein(a) [Lp(a)]-induced CCL1 expression in human macrophages requires TNFalpha and NF-kappaB activation: neutralizing anti-TNFalpha antibodies blocked Lp(a)-induced CCL1 mRNA; NF-kappaB inhibitor Bay 11-7082 blocked induction; EMSA confirmed Lp(a)-induced NF-kappaB binding to the CCL1 promoter in a TNFalpha-dependent manner. qRT-PCR, ELISA, neutralizing antibodies, NF-kappaB inhibitor, EMSA Life sciences High 19302817
2010 CCL1 neutralization prevents de novo conversion and suppressive function of regulatory T cells (Tregs) without affecting T effector cell function; combined anti-CCL1 and CpG-ODN treatment induces complete tumor rejection in BALB-neuT mice with long-term protective memory. Anti-CCL1 neutralizing antibody, in vivo tumor model, flow cytometry for lymphocyte composition Journal of immunology (Baltimore, Md. : 1950) Medium 20483762
2012 Carboxypeptidase M (CPM) cleaves CCL1 at its C-terminal basic amino acids (identified by mass spectrometry); C-terminal clipped CCL1 shows augmented CCR8-mediated intracellular calcium release and enhanced anti-apoptotic activity in BW5147 cells, despite reduced CCR8 binding affinity. Mass spectrometry identification of CCL1 as CPM substrate, calcium flux assay, CCR8 binding assay, apoptosis assay, carboxypeptidase inhibitor control PloS one High 22479563
2012 RhoA activation (via bacterial CNF toxins) triggers CCL1/I-309 secretion in an auto/paracrine manner, which then activates the JAK-STAT3 pathway; CCL1 was identified as the essential secreted factor mediating RhoA-induced STAT3 activation; pathway requires ROCK, JNK, and AP1-induced protein synthesis. Bacterial CNF toxin treatment, RhoA activation assay, STAT3 phosphorylation assay, siRNA/inhibitor dissection, CCL1 ELISA The Journal of biological chemistry High 22311973
2013 CCL1 expressed by lymph node lymphatic sinuses controls active tumor cell entry into lymph nodes via CCR8: blocking CCR8 with soluble antagonist or shRNA knockdown significantly decreased lymph node metastasis in a mouse model; tumor cells arrest at the junction of collecting lymphatics with the subcapsular sinus upon CCR8 inhibition. CCR8 shRNA knockdown, CCR8 antagonist, in vitro migration assay with blocking antibodies, in vivo mouse metastasis model, intravital imaging The Journal of experimental medicine High 23878309
2013 CCL1 in the spinal dorsal horn contributes to neuropathic pain: spinal application of recombinant CCL1 enhanced excitatory synaptic transmission in substantia gelatinosa neurons, induced phosphorylation of NMDA receptor subunits NR1 and NR2B, and evoked allodynia preventable by NMDA receptor antagonist MK-801; CCR8 was upregulated in spinal neurons, microglia, and astrocytes after nerve ligation; prophylactic anti-CCL1 antibody and CCR8 knockdown attenuated tactile allodynia. Patch-clamp recordings from spinal cord slices, intrathecal injection, Western blot for NMDA receptor phosphorylation, neutralizing antibody, siRNA knockdown, behavioral pain testing Cell death & disease High 23788036
2014 The 3D crystal structure of Ser-CCL1 (glycosylated and non-glycosylated forms) was determined by X-ray crystallography at 2.1-2.7 Å resolution using quasi-racemic and racemic mixtures; N-glycosylation does not significantly alter protein structure; the N-linked GlcNAc sugar is the only well-ordered glycan moiety. Total chemical synthesis by native chemical ligation, quasi-racemic and racemic crystallization, X-ray crystallography Angewandte Chemie (International ed. in English) High 24692304
2014 N-glycosylation of CCL1 affects its chemotactic activity: systematic comparison of glycosylated and non-glycosylated forms of CCL1 and Ser-CCL1 (prepared by total chemical synthesis with defined glycan structures) demonstrated differences in chemotactic activity correlated with glycosylation state. Total chemical synthesis by native chemical ligation with defined N-glycan, chemotaxis assay Angewandte Chemie (International ed. in English) High 24644239
2019 Disruption of the CCL1-CCR8 axis promotes atherosclerosis: mice doubly deficient for CCL1 and ApoE exhibit enhanced atherosclerosis with reduced Treg content in aorta and spleen, reduced IL-10, and increased Th1/Th2 ratio; in vivo intravital microscopy and flow chamber assays confirmed an essential role for CCL1 in leukocyte recruitment to the vessel wall. CCL1/ApoE double-knockout mice, CCR8 blocking antibodies in LDLR-null mice, intravital microscopy, in vitro flow chamber assay, flow cytometry Journal of molecular and cellular cardiology High 31121182
2019 CCL1 produced by activated mouse and human ILC2s acts in an autocrine/paracrine feed-forward loop via CCR8 to regulate ILC2 proliferation: activated ILC2s are a major in vivo source of CCL1; CCL1-CCR8 signaling supports ILC2 capacity to protect against helminthic infections. In vitro and in vivo experiments with CCR8-deficient mice, flow cytometry, CCL1 ELISA, helminth infection model The Journal of experimental medicine High 31537642
2021 CCL1 drives pulmonary fibrosis through two distinct receptor pathways: (1) via CCR8 on fibroblasts promoting migration; (2) via AMFR (autocrine motility factor receptor), identified as a novel CCL1 receptor by mass spectrometry of CCL1 complexes, on fibroblasts promoting activation through ubiquitination of the ERK inhibitor Spry1, thus activating Ras-mediated profibrotic protein synthesis; targeted deletion of Ccl1 in alveolar macrophages and CD4+ T cells blunted pathology. Mass spectrometry of CCL1 complexes (AMFR identification), conditional cell-type-specific Ccl1 deletion, Ccr8 and Amfr deletion in fibroblasts, ubiquitination assay, Ras-ERK pathway activation assay, antibody blockade in vivo Immunity High 34407391
2023 CCL1 facilitates pulmonary fibrosis by promoting macrophage M2 polarization via AMFR: CCL1 recruits macrophages through CCR8 and drives M2 phenotype through AMFR via CREB/C/EBPβ signaling; deletion of either AMFR or CCR8 in macrophages protected mice from bleomycin-induced pulmonary fibrosis. AMFR and CCR8 macrophage-specific knockout mice, bleomycin PF model, in vitro CREB/C/EBPβ signaling assay, flow cytometry for M2 markers International immunopharmacology High 37220693
2017 Sox2 overexpression in breast cancer cells activates NF-κB-CCL1 signaling to recruit Tregs by reducing H3K27Me3 on promoter regions of p65 and Ccl1; recruited Tregs in turn upregulate stemness properties of breast cancer cells in a paracrine manner. Chromatin immunoprecipitation for H3K27Me3, NF-κB reporter assay, Foxp3-EGFP mouse Treg isolation, sphere formation assay, flow cytometry Stem cells (Dayton, Ohio) Medium 29044882
2017 miR-20a-5p suppresses CCL1 expression by directly targeting the CCL1 3'UTR (validated by luciferase reporter assay); downregulation of miR-20a-5p due to promoter hypermethylation leads to increased CCL1 and IL-17 production in CD4+ T cells; overexpression of CCL1 rescues the effect of miR-20a-5p upregulation. Luciferase reporter assay, bisulfite sequencing PCR for promoter methylation, miRNA overexpression/knockdown, rescue experiments The British journal of ophthalmology Medium 28972028
2019 Subcutaneous CCL1 administration evokes thermal analgesia in mice through peripheral CCR8 receptors on leukocytes: analgesia was blocked by systemic (but not spinal) CCR8 antagonist R243, abolished by leukocyte depletion, and inhibited by CB2 receptor antagonist SR144528; elevated 2-arachidonoylglycerol (endocannabinoid) was detected by ELISA after CCL1 administration. Behavioral nociception assay (unilateral hot plate), c-Fos immunohistochemistry, leukocyte depletion (cyclophosphamide), CCR8 antagonist, CB2 receptor antagonist, 2-AG ELISA Cellular and molecular neurobiology Medium 31203533
2021 Intrathecal CCL1 evokes thermal analgesia via kappa-opioid receptors: analgesia was blocked by CCR8 antagonist R243, by microglial inhibitor minocycline (but not astrocyte inhibitor), by naloxone, and by kappa-opioid receptor antagonist nor-binaltorphimine and anti-dynorphin A antibody; endogenous dynorphin acting on spinal kappa-opioid receptors is the mechanistic effector. Behavioral nociception assay, c-Fos immunohistochemistry, minocycline/aminoadipate inhibition, opioid receptor antagonists, anti-dynorphin antibody Fundamental & clinical pharmacology Medium 33905573
2025 ALKBH5 (m6A eraser) destabilizes Ccl1 mRNA by binding to it; ALKBH5 knockout increases Ccl1 expression, promoting Treg recruitment and protecting against LPS-induced acute lung injury; pharmacological ALKBH5 inhibition (DDO-2728) or recombinant Ccl1 administration recapitulates protective effects. Alkbh5 knockout and knock-in mice, m6A dot assay, RNA-seq, LPS ALI model, Treg quantification by flow cytometry, RIP assay Cell proliferation Medium 40254698
2024 c-Myc directly binds the CCL1 promoter to drive CCL1 transcription in glioma stem cells; SAHA (HDAC inhibitor) inhibits HDAC2, suppressing c-Myc binding to the CCL1 promoter and reducing CCL1 expression, thereby reducing Treg recruitment and alleviating tumor immunosuppression. Dual-luciferase reporter assay, chromatin immunoprecipitation (ChIP) for c-Myc at CCL1 promoter, HDAC2 inhibition, flow cytometry for Treg infiltration, intracranial xenograft mouse model Journal of neuro-oncology Medium 38652401
2007 CCL1-CCR8 interaction mediates macrophage aggregation and peritoneal adhesion development: CCR8 was upregulated on peritoneal macrophages at sites of peritoneal injury; CCL1 (produced by peritoneal macrophages and mesothelial cells) enhanced CCR8 expression autocrinally and promoted cell aggregation; CCR8-deficient mice or CCL1-neutralizing antibody-treated mice showed significantly reduced peritoneal adhesion. CCR8 gene-deficient mice, anti-CCL1 neutralizing antibody, in vitro cell aggregation assay, RT-PCR for plasminogen activator inhibitor-1 Journal of immunology (Baltimore, Md. : 1950) High 17404314
2025 Macrophage-derived CCL1 activates CCR8 on hepatic stellate cells (HSCs), promoting liver fibrosis through JAK/STAT signaling pathway activation, leading to HSC activation and impaired apoptosis. Co-culture experiments, JAK/STAT pathway inhibitors, Western blot for STAT phosphorylation, liver fibrosis mouse model Biochemical pharmacology Medium 40122149

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2008 IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17. Journal of immunology (Baltimore, Md. : 1950) 204 19050277
1997 Identification of CCR8: a human monocyte and thymus receptor for the CC chemokine I-309. The Journal of experimental medicine 177 9207005
2005 CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. Journal of immunology (Baltimore, Md. : 1950) 169 15814739
2013 Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses. The Journal of experimental medicine 157 23878309
1992 The human cytokine I-309 is a monocyte chemoattractant. Proceedings of the National Academy of Sciences of the United States of America 156 1557400
1997 Identification of CCR8, the receptor for the human CC chemokine I-309. The Journal of biological chemistry 147 9211859
1998 The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains. The Journal of biological chemistry 142 9417093
2006 Differential regulation of chemokine production by Fcgamma receptor engagement in human monocytes: association of CCL1 with a distinct form of M2 monocyte activation (M2b, Type 2). Journal of leukocyte biology 131 16735693
2000 Human NK cells express CC chemokine receptors 4 and 8 and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine, and I-309. Journal of immunology (Baltimore, Md. : 1950) 115 10754297
1994 The chemokines IL-8, monocyte chemoattractant protein-1, and I-309 are monomers at physiologically relevant concentrations. Journal of immunology (Baltimore, Md. : 1950) 105 8077676
2001 Autocrine antiapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309. Blood 100 11493464
2021 The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis. Immunity 98 34407391
2002 Adenosine monophosphoramidase activity of Hint and Hnt1 supports function of Kin28, Ccl1, and Tfb3. The Journal of biological chemistry 96 11805111
2006 Aryl hydrocarbon receptor- and calcium-dependent induction of the chemokine CCL1 by the environmental contaminant benzo[a]pyrene. The Journal of biological chemistry 92 16679317
2017 Sox2 Communicates with Tregs Through CCL1 to Promote the Stemness Property of Breast Cancer Cells. Stem cells (Dayton, Ohio) 91 29044882
2010 Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses. Journal of immunology (Baltimore, Md. : 1950) 91 20483762
2000 CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation 83 10942748
2008 Statins induce regulatory T cell recruitment via a CCL1 dependent pathway. Journal of immunology (Baltimore, Md. : 1950) 79 18714025
2002 Skin-homing CLA+ T cells and regulatory CD25+ T cells represent major subsets of human peripheral blood memory T cells migrating in response to CCL1/I-309. European journal of immunology 77 12442333
2022 Tumor-derived exosomes drive pre-metastatic niche formation in lung via modulating CCL1+ fibroblast and CCR8+ Treg cell interactions. Cancer immunology, immunotherapy : CII 74 35428909
2012 Normal ageing is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes. Clinical and experimental immunology 72 23039889
2001 The chemokine receptor CCR8 mediates human endothelial cell chemotaxis induced by I-309 and Kaposi sarcoma herpesvirus-encoded vMIP-I and by lipoprotein(a)-stimulated endothelial cell conditioned medium. Blood 72 11133740
2000 I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo. Blood 72 11110671
1994 Inhibition of in vivo tumor growth by the beta chemokine, TCA3. Journal of immunology (Baltimore, Md. : 1950) 72 7963535
1996 I-309/T cell activation gene-3 chemokine protects murine T cell lymphomas against dexamethasone-induced apoptosis. Journal of immunology (Baltimore, Md. : 1950) 69 8805659
1998 Identification of CCR8 as the specific receptor for the human beta-chemokine I-309: cloning and molecular characterization of murine CCR8 as the receptor for TCA-3. Journal of immunology (Baltimore, Md. : 1950) 65 9469461
2002 Kin28 is found within TFIIH and a Kin28-Ccl1-Tfb3 trimer complex with differential sensitivities to T-loop phosphorylation. Molecular and cellular biology 64 11839796
2007 Recruitment and activation of macrophages by pathogenic CD4 T cells in type 1 diabetes: evidence for involvement of CCR8 and CCL1. Journal of immunology (Baltimore, Md. : 1950) 63 17947648
1999 Sequence polymorphisms in the chemokines Scya1 (TCA-3), Scya2 (monocyte chemoattractant protein (MCP)-1), and Scya12 (MCP-5) are candidates for eae7, a locus controlling susceptibility to monophasic remitting/nonrelapsing experimental allergic encephalomyelitis. Journal of immunology (Baltimore, Md. : 1950) 61 10438970
1990 Sequence and chromosomal location of the I-309 gene. Relationship to genes encoding a family of inflammatory cytokines. Journal of immunology (Baltimore, Md. : 1950) 59 2212659
2019 A CCL1/CCR8-dependent feed-forward mechanism drives ILC2 functions in type 2-mediated inflammation. The Journal of experimental medicine 58 31537642
2018 CCL1 is a major regulatory T cell attracting factor in human breast cancer. BMC cancer 57 30572845
2007 Inhibition of CCL1-CCR8 interaction prevents aggregation of macrophages and development of peritoneal adhesions. Journal of immunology (Baltimore, Md. : 1950) 56 17404314
2013 CCL-1 in the spinal cord contributes to neuropathic pain induced by nerve injury. Cell death & disease 54 23788036
1994 Biologic activities of the murine beta-chemokine TCA3. Journal of immunology (Baltimore, Md. : 1950) 51 7963534
2003 CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I. European journal of immunology 48 12645948
2002 Increased responsiveness of murine eosinophils to MIP-1beta (CCL4) and TCA-3 (CCL1) is mediated by their specific receptors, CCR5 and CCR8. Journal of leukocyte biology 46 12050188
2013 Possible involvement of CCL1-CCR8 interaction in lymphocytic recruitment in IgG4-related sclerosing cholangitis. Journal of hepatology 45 23811304
2020 Human Adipose-Derived Mesenchymal Stem Cells-Derived Exosomal microRNA-19b Promotes the Healing of Skin Wounds Through Modulation of the CCL1/TGF-β Signaling Axis. Clinical, cosmetic and investigational dermatology 43 33364805
2000 Inhibition by IL-12 and IFN-alpha of I-309 and macrophage-derived chemokine production upon TCR triggering of human Th1 cells. European journal of immunology 43 10760790
2017 Lack of the COMPASS Component Ccl1 Reduces H3K4 Trimethylation Levels and Affects Transcription of Secondary Metabolite Genes in Two Plant-Pathogenic Fusarium Species. Frontiers in microbiology 42 28119673
2015 Fibroblast ERα promotes bladder cancer invasion via increasing the CCL1 and IL-6 signals in the tumor microenvironment. American journal of cancer research 41 26045993
1995 Biologic activities of the beta-chemokine TCA3 on neutrophils and macrophages. Journal of immunology (Baltimore, Md. : 1950) 41 7730638
1988 The expression and regulation of a potential lymphokine gene (TCA3) in CD4 and CD8 T cell clones. Journal of immunology (Baltimore, Md. : 1950) 41 2457620
2014 (Quasi-)racemic X-ray structures of glycosylated and non-glycosylated forms of the chemokine Ser-CCL1 prepared by total chemical synthesis. Angewandte Chemie (International ed. in English) 40 24692304
2019 Disruption of the CCL1-CCR8 axis inhibits vascular Treg recruitment and function and promotes atherosclerosis in mice. Journal of molecular and cellular cardiology 38 31121182
2017 Participation of CCL1 in Snail-Positive Fibroblasts in Colorectal Cancer Contribute to 5-Fluorouracil/Paclitaxel Chemoresistance. Cancer research and treatment 37 28934847
2017 MicroRNA-20a-5p suppresses IL-17 production by targeting OSM and CCL1 in patients with Vogt-Koyanagi-Harada disease. The British journal of ophthalmology 37 28972028
2017 Spinal CCL1/CCR8 signaling interplay as a potential therapeutic target - Evidence from a mouse diabetic neuropathy model. International immunopharmacology 36 28961489
2014 Total chemical synthesis and biological activities of glycosylated and non-glycosylated forms of the chemokines CCL1 and Ser-CCL1. Angewandte Chemie (International ed. in English) 34 24644239
2006 A single nucleotide polymorphism in the CCL1 gene predicts acute exacerbations in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 34 16864713
1990 Expression and characterization of TCA3: a murine inflammatory protein. Journal of immunology (Baltimore, Md. : 1950) 34 2212660
1996 Subunits of yeast RNA polymerase II transcription factor TFIIH encoded by the CCL1 gene. The Journal of biological chemistry 33 8557668
2021 Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and Adenosine Deaminase Activity Distinguishes Active From Remotely Acquired Latent Tuberculosis. Frontiers in immunology 32 34691031
2006 Structure/function relationships of CCR8 agonists and antagonists. Amino-terminal extension of CCL1 by a single amino acid generates a partial agonist. The Journal of biological chemistry 31 17023422
2012 Expression of CCL1 and CCL18 in atopic dermatitis and psoriasis. Clinical and experimental dermatology 29 22680616
2008 Oncostatin M-induced and constitutive activation of the JAK2/STAT5/CIS pathway suppresses CCL1, but not CCL7 and CCL8, chemokine expression. Journal of immunology (Baltimore, Md. : 1950) 28 18981157
2000 Human CC chemokine I-309, structural consequences of the additional disulfide bond. Biochemistry 28 10821677
1997 HIV-1-specific cell-mediated immunity is enhanced by co-inoculation of TCA3 expression plasmid with DNA vaccine. Immunology 27 9038705
1997 Rig2, a RING finger protein that interacts with the Kin28/Ccl1 CTD kinase in yeast. Molecular & general genetics : MGG 27 9294030
2015 Genetic polymorphisms of CCL1 rs2072069 G/A and TLR2 rs3804099 T/C in pulmonary or meningeal tuberculosis patients. International journal of clinical and experimental pathology 25 26722451
2003 Human cord blood-derived mast cells synthesize and release I-309 in response to IgE. Life sciences 25 12967681
1996 The rapeseed mitochondrial gene encoding a homologue of the bacterial protein Ccl1 is divided into two independently transcribed reading frames. Molecular & general genetics : MGG 25 8842149
1996 Beta-chemokine TCA3 binds to mesangial cells and induces adhesion, chemotaxis, and proliferation. Journal of immunology (Baltimore, Md. : 1950) 24 8543828
1996 Ccl1, a cyclin associated with protein kinase Kin28, controls the phosphorylation of RNA polymerase II largest subunit and mRNA transcription. Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie 24 8761664
1996 Beta-chemokine TCA3 binds to and activates rat vascular smooth muscle cells. Journal of immunology (Baltimore, Md. : 1950) 23 8757339
2019 Peritumoural CCL1 and CCL22 expressing cells in hepatocellular carcinomas shape the tumour immune infiltrate. Pathology 21 31445808
2007 Combination of 17beta-estradiol with the environmental pollutant TCDD is involved in pathogenesis of endometriosis via up-regulating the chemokine I-309-CCR8. Fertility and sterility 20 17693327
2016 IL-11 and CCL-1: Novel Protein Diagnostic Biomarkers of Lung Adenocarcinoma in Bronchoalveolar Lavage Fluid (BALF). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 19 27524264
2012 C-terminal clipping of chemokine CCL1/I-309 enhances CCR8-mediated intracellular calcium release and anti-apoptotic activity. PloS one 19 22479563
1994 Transcriptional regulation of the TCA3 gene in mast cells after Fc epsilon RI cross-linking. Journal of immunology (Baltimore, Md. : 1950) 19 8207245
2023 The chemokine CCL1 facilitates pulmonary fibrosis by promoting macrophage migration and M2 polarization. International immunopharmacology 17 37220693
2012 Toxin-induced RhoA activity mediates CCL1-triggered signal transducers and activators of transcription protein signaling. The Journal of biological chemistry 17 22311973
2019 Spinal CCL1/CCR8 regulates phosphorylation of GluA1-containing AMPA receptor in postoperative pain after tibial fracture and orthopedic surgery in mice. Neuroscience research 16 31121204
2000 A transcriptional autoregulatory loop for KIN28-CCL1 and SRB10-SRB11, each encoding RNA polymerase II CTD kinase-cyclin pair, stimulates the meiotic development of S. cerevisiae. Yeast (Chichester, England) 15 10861906
2021 Hsa_circ_0134111 promotes osteoarthritis progression by regulating miR-224-5p/CCL1 interaction. Aging 14 34413269
2017 Neuropathic pain inhibitor, RAP-103, is a potent inhibitor of microglial CCL1/CCR8. Neurochemistry international 14 29248693
2002 Overexpression of ccl1-2 can bypass the need for the putative apocytochrome chaperone CycH during the biogenesis of c-type cytochromes. Molecular microbiology 14 12421312
1999 Role of the C-C chemokine, TCA3, in the protective anticryptococcal cell-mediated immune response. Journal of immunology (Baltimore, Md. : 1950) 14 10202026
1993 Serologic analysis of a murine chemokine, TCA3. Journal of immunology (Baltimore, Md. : 1950) 14 7678629
2020 CCL1 blockade alleviates human mesenchymal stem cell (hMSC)-induced pulmonary fibrosis in a murine sclerodermatous graft-versus-host disease (Scl-GVHD) model. Stem cell research & therapy 13 32586381
2009 TNFalpha- and NF-kappaB-dependent induction of the chemokine CCL1 in human macrophages exposed to the atherogenic lipoprotein(a). Life sciences 11 19302817
1996 Activated lymphocytes induce promoter activity of the TCA3 gene in mast cells following cell-to-cell contact. Biochemical and biophysical research communications 11 8629992
2024 Suberanilohydroxamic acid (SAHA), a HDAC inhibitor, suppresses the effect of Treg cells by targeting the c-Myc/CCL1 pathway in glioma stem cells and improves PD-L1 blockade therapy. Journal of neuro-oncology 10 38652401
2015 The Ccl1-Kin28 kinase complex regulates autophagy under nitrogen starvation. Journal of cell science 10 26567215
2006 In vitro selection of RNA aptamers that block CCL1 chemokine function. Biochemical and biophysical research communications 10 16930539
2011 Identification of CCL1 as a Gene Differentially Expressed in CD4 T Cells Expressing TIM-3. Immune network 9 22039368
2021 CCR8 Signaling via CCL1 Regulates Responses of Intestinal IFN-γ Producing Innate Lymphoid CelIs and Protects From Experimental Colitis. Frontiers in immunology 8 33613532
2021 Overexpressing Pleurotus ostreatus rho1b results in transcriptional upregulation of the putative cellulolytic enzyme-encoding genes observed in ccl1 disruptants. Environmental microbiology 8 34622510
2006 Selective neutralization of the chemokine TCA3 reduces the increased injury of partial versus whole liver transplants induced by cold preservation. Transplantation 8 17164723
2003 Yaba-like disease virus protein 7L is a cell-surface receptor for chemokine CCL1. The Journal of general virology 8 14645913
2025 Inhibition of Alkbh5 Attenuates Lipopolysaccharide-Induced Lung Injury by Promoting Ccl1 m6A and Treg Recruitment. Cell proliferation 6 40254698
2004 Autocrine stimulation of rhadinovirus-transformed T cells by the chemokine CCL1/I-309. Oncogene 6 15378023
2003 Ty3/gypsy-like retrotransposons in Candida albicans and Candida dubliniensis: Tca3 and Tcd3. Yeast (Chichester, England) 6 12722183
2019 The Systemic Administration of the Chemokine CCL1 Evokes Thermal Analgesia in Mice Through the Activation of the Endocannabinoid System. Cellular and molecular neurobiology 5 31203533
2025 Interaction between nasal epithelial cells and Tregs in allergic rhinitis responses to allergen via CCL1/CCR8. Frontiers in immunology 4 40051629
2025 Macrophage-derived CCL1 targets CCR8 receptor in hepatic stellate cells to promote liver fibrosis through JAk/STAT pathway. Biochemical pharmacology 4 40122149
2023 MMP9-Associated Tumor Stem Cells, CCL1-Silenced Dendritic Cells, and Cytokine-Induced Killer Cells Have a Remarkable Therapeutic Efficacy for Acute Myeloid Leukemia by Activating T Cells. Stem cells international 4 37200633
2021 Kappa-opioid receptor-mediated thermal analgesia evoked by the intrathecal administration of the chemokine CCL1 in mice. Fundamental & clinical pharmacology 4 33905573
2020 Chemical Synthesis of Ubiquitinated High-Mannose-Type N-Glycoprotein CCL1 in Different Folding States. The Journal of organic chemistry 4 32985191